Sangrix Inc. filed a Form 6-K with the U.S. Securities and Exchange Commission on November 17, 2026, disclosing the completion of a 1-for-8 reverse stock split that took effect on November 16, 2026, following shareholder approval at an extraordinary general meeting held on November 3, 2026.

Key Highlights

  • Reverse split ratio: Every eight Class A or Class B ordinary shares were consolidated into one share, effective November 16, 2026.
  • Share count reduced: Outstanding Class A ordinary shares fell from 4,035,192 to approximately 504,399; Class B ordinary shares fell from 96,043 to approximately 12,006.
  • Par value increased: Par value per share rose from US$0.0003 to US$0.0024 for both Class A and Class B ordinary shares.
  • New CUSIP: The CUSIP number following the reverse stock split is G21621142.
  • Convertible debentures: The company disclosed four outstanding secured convertible debentures with an aggregate outstanding principal amount of approximately $8.44 million.
  • Warrants adjusted: Warrants to purchase 192,154 Class A ordinary shares at $1.63 per share, and a pre-funded warrant adjusted from 1,291,573 to approximately 161,447 shares, are subject to proportional adjustment per the filing.
  • Compliance purpose: The reverse stock split is intended for the company to maintain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.

Sangrix Discloses Share Consolidation Details and Warrant Adjustments

According to the Form 6-K filed by Sangrix Inc. (NASDAQ:SGRX), shareholders approved the reverse stock split at an extraordinary general meeting held on November 3, 2026, at 9:00 p.m. Singapore Time. The consolidation combined every eight Class A ordinary shares and every eight Class B ordinary shares, each previously carrying a par value of US$0.0003, into one share with a par value of US$0.0024. The company reported that trading on the Nasdaq Stock Market on a post-split basis under the symbol "SGRX" commenced upon the opening of the market on November 16, 2026. No fractional shares will be issued; instead, the filing states that any shareholder entitled to a fractional share will receive one full post-split share.

The filing also addressed the impact on outstanding derivative securities. The company disclosed four secured convertible debentures with an aggregate outstanding principal amount of approximately $8.44 million. The filing states that if the "Event Market Price," calculated as the average of the five lowest volume-weighted average prices during a specified 15-consecutive-trading-day window, is below the adjusted conversion price, the conversion price will be reduced to that level on the 16th trading day after the effective date. For warrants to purchase 192,154 Class A ordinary shares at $1.63 per share, a comparable "Warrant Event Market Price" mechanism applies over a 20-consecutive-trading-day window. The pre-funded warrant, previously exercisable for 1,291,573 Class A ordinary shares at US$0.0003 per share, has been adjusted to approximately 161,447 shares at US$0.0024 per share.

The filing states that authorized ordinary shares will be reduced in proportion to the split ratio, to 23,750,000,000 Class A ordinary shares and 1,250,000,000 Class B ordinary shares. The company also indicated it will amend and restate its memorandum and articles of association to reflect these changes. The filing was signed by Jinghai Jiang, Chief Executive Officer, Chief Operating Officer, and Chairman of the Board.

What Was Disclosed

Sangrix Inc. reported the completion of a 1-for-8 reverse stock split effective November 16, 2026, reducing outstanding Class A shares to approximately 504,399 and Class B shares to approximately 12,006, with proportional adjustments to outstanding warrants and convertible debentures disclosed in detail.